Key facts: RxSight Q3 Revenue Falls 19%; Lens Designs; Target Falls

What happened

RxSight reported third-quarter 2026 revenue of $24.6 million, down 19% from a year earlier, while lens sales fell by 2,917 units and its GAAP net loss widened to $16.2 million. The company announced designs for next-generation LAL and LAL+ lenses and an LAL Toric lens for post-surgical astigmatism correction.

Confirmed

Global impact / market context

Lower revenue and fewer lens sales indicate weaker current demand, while a wider net loss means more costs exceeded income. New lens designs could help RxSight address more vision-correction needs, but designs alone do not establish when products will launch or whether sales will recover.

Analyst inference

The reported $254.7 million in cash and investments provides a financial buffer, but the article gives no spending forecast or launch timetable. Analysts’ average 12-month target declined to $7.19 from $7.57, while 10 analysts maintained a Hold consensus.

Confirmed

What to watch

1. Watch for subsequent revenue and lens-unit sales: continued declines would indicate that weaker demand is persisting and could constrain the company’s ability to cover its costs. Analyst inference
2. Look for announcements on launch timing and availability of the next-generation LAL and LAL+ designs and the LAL Toric lens; the article reports designs, not launches. Analyst inference
3. Track whether the net loss narrows and how cash and investments change from the reported $254.7 million, since losses and spending can reduce funds available. Analyst inference

Evidence

• Original source link unavailable